Genolution

Genolution Altman Z-Score

The Altman Z-Score of Genolution (225220.KQ) as of Oct 22, 2026 is 1.23. In the previous year, Altman Z-Score was 1.27 — a change of -3.36% (lower).

Altman Z-Score

1.23

YoY

-3.36%

Last updated:

Altman Z-Score of Genolution is 2025 1.23 . Altman Z-Score of Genolution was 2024 1.27 . It decreases by -3.36% lower compared to the previous year.

The Genolution Altman Z-Score history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Altman Z-Score
Date
Altman Z-Score
Jan 1, 2018
2.08 KRW
Jan 1, 2019
1.57 KRW
Jan 1, 2020
4.46 KRW
Jan 1, 2021
4.64 KRW
Jan 1, 2022
2.60 KRW
Jan 1, 2023
1.39 KRW
Jan 1, 2024
1.27 KRW
Jan 1, 2025
1.23 KRW
The Genolution Altman Z-Score history
YEARAltman Z-ScoreYoY
1.23-3.36%
1.27-8.49%
1.39-46.70%
2.60-43.92%
4.64+3.93%
4.46+183.39%
1.57-24.46%
2.08-92.60%
28.16-16.77%
33.83—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Altman Z-Score of Genolution is 1.23 in 2025.

On Eulerpool you can find the complete historical development of Altman Z-Score Genolution since 2006 – with annual values, charts, and detailed analysis.

The Altman Z-Score predicts bankruptcy probability using five financial ratios. Scores above 3.0 indicate safety, below 1.8 suggests distress risk.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Genolution

All Key Metrics — Genolution